rld2102
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 21, 2021 (NCT05155995)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06518122 | Phase 1 | Aug 31, 2024 | Hanmi Pharmaceutical, Jeonbuk National University |
| NCT06357910 | Phase 1 | May 17, 2024 | Hanmi Pharmaceutical, Jeonbuk National University |
| NCT06346184 | Phase 1 | May 2, 2024 | Hanmi Pharmaceutical, Jeonbuk National University |
| NCT05155995 | Phase 1 | Oct 21, 2021 | Chonbuk National University, Hanmi Pharmaceutical |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hanmi Pharmaceutical | For profit | 4 | 4 | 1 | 2021 |
| Jeonbuk National University | Academic/Hospital | 3 | 0 | 1 | 2024 |
| Chonbuk National University | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1